Grand Pharmaceutical Group Limited 0512

Angelalign Technology Inc. (6699.HK) ("Angel") http://www.angelaligner.com, a global trailblazer in orthodontic clear aligner technology, today announced the launch of Pressure Points in the European market, an upgraded feature that replaces the company's current Torque Ridges. The upgrade reflects Angel's continued commitment to innovation focused on solving orthodontists' clinical challenges.

Treasuries pay more today, but these three healthcare dividend payers offer something Treasuries can't: growth in both the payout and the stock.

AstraZeneca PLC (NASDAQ:AZN) said on September 28 that it will make a $2 billion equity investment in Summit Therapeutics, Inc. (NASDAQ:SMMT) and run joint trials of the two companies’ cancer drugs. The money buys preferred shares convertible into common stock at an equivalent of $18.36 each, a premium to Summit’s September 28 close of $15.48. […]

Align Technology (NasdaqGS:ALGN) has been highlighted as a key participant in new reports on the global dental equipment market. Researchers cite emerging demand for digital dentistry tools and cosmetic treatments as major drivers in these market assessments. The reports position Align Technology alongside other dental equipment suppliers as exposure to these themes attracts fresh investor attention. Align being profiled as a major player in dental equipment growth is useful context, but not...

Bank of America nearly doubled its peak sales estimate for one Johnson & Johnson drug ahead of the company’s third-quarter earnings.

NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that Moderna, Inc. (Nasdaq: MRNA) will become a component of the Nasdaq-100 Index® (NDX®) replacing Warner Bros. Discovery, Inc. (Nasdaq: WBD) prior to market open on Friday, October 9, 2026. For additional information, including notifications on changes to any Nasdaq Indexes, please go to https://indexes.nasdaq.com/ About Nasdaq Global Indexes Nasdaq Global Indexes is one of the world's leading index providers, of

The company extended its existing partnership with a major pharmacy chain.

Shares of diversified science and technology company Danaher (NYSE:DHR) fell 3.9% in the afternoon session after the company announced that Julie Sawyer Montgomery assumed the roles of president and chief executive officer and joined the board of directors.

In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival observed to date in first-line EGFR exon20ins NSCLC After agreement with the U.S. FDA, Real-Time Oncology Review program submission process initiated; completion of NDA submission expected by year-end 2026 CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or be

Gossamer Bio’s modeled fair value has shifted from US$1.66 to US$82.48, reflecting the 1 for 80 reverse stock split and refreshed valuation work. Street research links these reset price targets to a split view on risk and reward for seralutinib as it moves toward a planned PAH NDA submission, with analysts weighing FDA feedback, trial data and single asset concentration. As you read on, you will see how to track these changing targets and what might matter most for following the evolving...

Curaleaf International, part of Curaleaf Holdings, Inc. (TSX:CURA) in partnership with Jupiter Research LLC, today announced that its Que Medical Inhalation Device (QMID) is available in Australia, following the registration by Australia's Therapeutic Goods Administration (TGA), on 15 September 2026. One year after receiving EU Medical Device Registration, QMID is listed as a Class IIb Medical Device in the Australian Register of Therapeutic Goods (ARTG), making it the first device intended for

TORONTO and HOUSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting cancer and autoimmune diseases, today announced the voting results from the Company’s annual general and special meeting of shareholders held today, October 1, 2026 (the “Meeting”). Medicenna is pleased to announce that all of the nominees listed in its management information circul

AbbVie boasts stronger revenue growth and free cash flow, while Bristol Myers Squibb trades at half the valuation with nearly double the profit margin.

Inflation is running hot, and the Fed is raising interest rates, but consumers aren't likely to pull back on the products these companies sell.

WINNIPEG, MB / ACCESS Newswire / October 1, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today announced the granting of stock options (the "Options") to certain directors, officers, employees and consultants of the Company to purchase a total of 150,000 common shares of the Company at a price of $2.

Shares of personal wellness company WeightWatchers (NASDAQ:WW) fell 10.3% in the afternoon session after accelerating use of GLP-1 weight-loss drugs kept weighing on demand for traditional behavioral diet subscriptions. The selloff builds on Wednesday's setup as the stock had bounced on a Google Health Enterprise / Fitbit collaboration for select employer programs, but that partnership did not reverse the structural shift toward medication-led weight loss. According to the Atlantic, GLP-1 therap